A Randomised Study Comparing Laser Therapy (Greenlight XPS™ Laser System) Versus Conventional Surgery (Transurethral Resection of the Prostate [TURP]) for the Treatment of Benign Prostatic Hyperplasia

ISRCTN	ISRCTN16280334
DOI	https://doi.org/10.1186/ISRCTN16280334
Protocol serial number	PE1006
Sponsor	American Medical Systems, Inc (USA)
Funder	American Medical Systems, Inc. (USA)

Submission date: 11/10/2010
Registration date: 26/10/2010
Last edited: 27/03/2018

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Urological and Genital Diseases

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Mr Andrew Thomas
Scientific

Princess of Wales Hospital
Department of Urology
Coity Rd
Bridgend
Mid Glamorgan
Wales
CF31 1RQ
United Kingdom

Email	andyt7264@mac.com

Study information

Primary study design	Interventional
Study design	Prospective multicentre randomised active controlled parallel group trial
Secondary study design	Randomised parallel trial
Study type	Participant information sheet
Scientific title	A Prospective Multicentre Randomised Study Comparing Photoselective Vaporisation of the Prostate with the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia
Study acronym	Greenlight XPS vs. TURP
Study objectives	To demonstrate that Benign Prostatic Hyperplasia (BPH) symptoms after Photoselective Vaporisation (PVP) are not worse when compared to Transurethral Resection of the Prostate (TURP) at 6 months post procedure measured via international prostate symptom score (IPSS) for the treatment of BPH.
Ethics approval(s)	Ethics Committee approval to be submitted
Health condition(s) or problem(s) studied	Benign Prostatic Hyperplasia (BPH)
Intervention	Patients will be randomised to receive either 1. GreenLight XPS 532 nm Laser System with MoXy™ laser fiber 2. Monopolar or bipolar loop TURP systems carrying the CE mark
Intervention type	Procedure/Surgery
Primary outcome measure(s)	Severity of BPH symptoms 6 months post procedure measured by international prostate symptom score (IPSS)
Key secondary outcome measure(s)	1. Complication-free rates at 3 weeks post-procedure 2. Prostate volume (via TRUS or abdominal ultrasonography) as reported on the case report forms at baseline and 6-month follow-up visit 3. Functional status, measured by maximum urinary flow rate (Qmax) at 3, 6, 12, and 24-month follow-up visits (The proportion of subjects with a Qmax of 15ml/s or greater will be noted) 4. Immediate post intervention outcomes of PVP and TURP 4.1. Short Form Health Survey (SF-36) Acute at baseline and 3-week visit 4.2 Length of stay 5. Health status, measured at 3, 6, 12, and 24 month follow-up visit 5.1. International prostate symptom score (IPSS) 5.2. BPH Impact Index (BII) 5.3. Over-active Bladder Questionnaire (OABq) 5.4. SF-36 Acute 5.5. EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D) 6. Tolerability, measured at 6, 12 and 24 month follow-up visit 6.1. International Index of Erectile Function (IIEF) 6.2. International Consultation on Incontinence Questionnaire Short Form 7. Subject satisfaction, measured at end of study 8. Rate of re-treatment, measured at end of study
Completion date	12/01/2014

Eligibility

Participant type(s)	Patient
Age group	Adult
Lower age limit	18 Years
Sex	All
Target sample size at registration	252
Key inclusion criteria	1. Subject has provided informed consent 2. Subject has diagnosis of benign prostatic hyperplasia 3. Subject is willing to be randomised 4. Clinical investigator has documented in the subjects medical record that in his/her judgment the subject is a surgical candidate for either the PVP or the TURP procedure and may be randomised into either arm 5. Subject is greater than or equal to 40 years of age 6. Subject has an International Prostate Symptom Score (IPSS) score greater than or equal to 12 measured at the baseline visit 7. Subject has medical record documentation of a maximum urinary flow rate (Qmax) less than 15ml/s (If uroflow testing documentation is available within 90 days prior to the informed consent date, and the sample is greater than or equal to 125ml, and the Qmax is less than 15ml/s it may be used for the inclusion/exclusion criteria) 8. Subject has medical record documentation of a prostate volume of less than or equal to 100g by transrectal ultrasound (TRUS) or abdominal ultrasound (If TRUS or abdominal ultrasound testing documentation is available within the 180 days prior to the informed consent date and the prostate volume is less than or equal to 100g, it may be used for the inclusion/exclusion criteria) 9. Subject is classified as American Society of Anesthesiologist (ASA) I, II or III 10. Subject has a serum creatinine less than 1.8 mg/dl measured after the date of the informed consent and prior to the surgical procedure
Key exclusion criteria	1. Subject has a life expectancy of less than 2 years 2. Subject is currently enrolled in, or plans to enroll in, any concurrent drug or device study unless pre-approved by the sponsor 3. Subject has an active infection (eg, urinary tract infection or prostatitis) 4. Subject has a history of 2 or more urinary tract infections in the 365 days prior to the informed consent date 5. Subject has a diagnosis of chronic bacterial prostatitis or chronic pelvic pain syndrome (eg, non-bacterial chronic prostatitis) 6. Subject has been diagnosed with a urethral stricture or bladder neck contracture within the 180 days prior to the informed consent date 7. Subject has been diagnosed with 2 or more urethral strictures and/or bladder neck contractures within the 5 years prior to the informed consent date 8. Subject has a neurogenic bladder or other neurological disorder that would impact bladder function (eg, multiple sclerosis, Parkinsons disease, spinal cord injuries) 9. Subject has a diagnosis of diabetic cystopathy 10. Subject has history of lower urinary tract surgery (eg, urinary diversion, artificial urinary sphincter, penile prosthesis) 11. Subject has diagnosis of stress urinary incontinence that requires treatment or daily pad/device use 12. Subject has a history of intermittent self catheterisation within the 180 days prior to the informed consent date 13. Subject has current diagnosis of bladder stones 14. Subject has diagnosis of prostate cancer 15. Subject has a history of T1 or CIS bladder cancer 16. Subject has damage to external urinary sphincter 17. Subject has a medical contraindication for undergoing either TURP or PVP surgery (eg, infection, coagulopathy or significant cardiac or other medical risk factors for surgery) 18. Subject has a disorder of the coagulation cascade (eg, haemophilia) or disorders that affect platelet count or function (eg, Von Willebrands disease) that would put the subject at risk for intraoperative or postoperative bleeding 19. Subject is unable to discontinue anticoagulant and antiplatelet therapy preoperatively (3-5 days) 20. Subject has had an acute myocardial infarction, open heart surgery or cardiac arrest less than 180 days prior to the date of informed consent 21. Subject is immunocompromised (eg, organ transplant, leukaemia)
Date of first enrolment	12/01/2010
Date of final enrolment	12/01/2014

Locations

Countries of recruitment

United Kingdom
Wales
Germany
Netherlands

Study participating centre

Princess of Wales Hospital

Wales
CF31 1RQ
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
IPD sharing plan

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes

Editorial Notes

27/03/2018: No publications found, verifying study status with principal investigator.
16/02/2016: No publications found, verifying study status with principal investigator